Factory Mutual Insurance Co. cut its stake in Pfizer Inc. (NYSE:PFE) by 17.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,794,451 shares of the biopharmaceutical company’s stock after selling 391,851 shares during the quarter. Factory Mutual Insurance Co.’s holdings in Pfizer were worth $78,328,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. OppenheimerFunds Inc. boosted its stake in Pfizer by 32.2% during the third quarter. OppenheimerFunds Inc. now owns 6,890,372 shares of the biopharmaceutical company’s stock valued at $303,659,000 after buying an additional 1,678,438 shares during the period. Prio Wealth Limited Partnership lifted its stake in shares of Pfizer by 3.2% in the 3rd quarter. Prio Wealth Limited Partnership now owns 1,039,655 shares of the biopharmaceutical company’s stock valued at $45,817,000 after acquiring an additional 32,071 shares during the last quarter. Rehmann Capital Advisory Group lifted its stake in shares of Pfizer by 1.4% in the 3rd quarter. Rehmann Capital Advisory Group now owns 125,426 shares of the biopharmaceutical company’s stock valued at $5,528,000 after acquiring an additional 1,759 shares during the last quarter. Focused Wealth Management Inc lifted its stake in shares of Pfizer by 160.7% in the 3rd quarter. Focused Wealth Management Inc now owns 83,780 shares of the biopharmaceutical company’s stock valued at $3,692,000 after acquiring an additional 51,644 shares during the last quarter. Finally, Sterling Capital Management LLC lifted its stake in shares of Pfizer by 16.6% in the 2nd quarter. Sterling Capital Management LLC now owns 2,478,848 shares of the biopharmaceutical company’s stock valued at $89,933,000 after acquiring an additional 353,212 shares during the last quarter. Institutional investors own 69.49% of the company’s stock.
In other news, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $42.83, for a total value of $642,450.00. Following the completion of the sale, the insider now directly owns 124,994 shares in the company, valued at approximately $5,353,493.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Douglas M. Lankler sold 5,000 shares of the company’s stock in a transaction on Friday, February 1st. The stock was sold at an average price of $42.75, for a total value of $213,750.00. Following the completion of the sale, the executive vice president now owns 83,592 shares of the company’s stock, valued at $3,573,558. The disclosure for this sale can be found here. Insiders have sold a total of 332,526 shares of company stock worth $14,346,539 over the last three months. Insiders own 0.09% of the company’s stock.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 29th. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.01. The business had revenue of $13.98 billion for the quarter, compared to analysts’ expectations of $13.92 billion. Pfizer had a return on equity of 26.02% and a net margin of 20.79%. The firm’s quarterly revenue was up 2.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.62 EPS. On average, research analysts predict that Pfizer Inc. will post 2.86 earnings per share for the current year.
A number of research firms have recently weighed in on PFE. Credit Suisse Group reissued a “neutral” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday, January 28th. Zacks Investment Research upgraded Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, April 10th. Bank of America boosted their price target on Pfizer from $45.00 to $48.00 and gave the company a “buy” rating in a report on Monday, April 1st. JPMorgan Chase & Co. restated a “neutral” rating and set a $46.00 price target on shares of Pfizer in a report on Friday. Finally, ValuEngine downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Thursday, January 24th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $45.61.
COPYRIGHT VIOLATION NOTICE: “Factory Mutual Insurance Co. Trims Stake in Pfizer Inc. (PFE)” was reported by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/pfizer-inc-pfe-shares-sold-by-factory-mutual-insurance-co.html.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Read More: Dividend
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.